Salivary and Serum Interleukin 1 Beta, Interleukin 6 and Tumor Necrosis Factor Alpha in Patients with Leukoplakia and Oral Cancer

Overview

Journal Med Oral Patol Oral Cir Bucal

Specialty Dentistry

Date 2011 Jul 12

PMID 21743397

Citations 56

Authors

Vlaho Brailo

Vanja Vucicevic-Boras

Josip Lukac

Dolores Biocina-Lukenda

Iva Zilic-Alajbeg

Aleksandar Milenovic

Melita Balija

Affiliations

Soon will be listed here.

Abstract

Objectives: The aim of study was to compare salivary and serum concentrations of interleukin 1 beta (IL-1β), interleukin 6 (IL-6) and tumor necrosis factor alpha (TNF-α) in patients with oral leukoplakia, oral cancer and healthy controls.

Study Design: Eighty eight patients (28 with oral cancer, 29 leukoplakia, and 31 healthy controls) were included in this study. Cytokine concentrations were measured by commercial enzyme linked immunoassay.

Results: Salivary IL-1β and IL-6 were significantly higher in oral cancer patients than in patients with leukoplakia and control group (p<0.05). No differences in concentrations of salivary TNF-α between either of the groups were observed. Serum concentrations of IL-1β were below level of detection in all but two participants. No significant differences between the groups were observed in serum concentrations of IL-6. Serum TNF-α was significantly higher in control subjects than in oral cancer patients.

Conclusions: Patients with oral cancer have elevated levels of inflammatory cytokines in their saliva. Whether this elevation can be used for monitoring the malignant transformation of oral leukoplakia remains to be answered by further follow up studies.

Citing Articles

Efficacy of Rapid Salivary C-Reactive Protein Test to Assess Early Changes in Malignancy in the Oral Cavity and Its Utility in Screening for Oral Cancer.

Patil V, Vineetha R, Smriti K, Pentapati K, Gadicherla S, Sunitha C Dent J (Basel). 2025; 13(1).

PMID: 39851610 PMC: 11763824. DOI: 10.3390/dj13010034.

Evaluation of salivary biomarker interleukin-6 in oral squamous cell carcinoma and oral potentially malignant disorders - A comparative cross-sectional South Indian study.

Chundru V, Madhavan R, Chintala L, Boyapati R, Srikar M J Oral Maxillofac Pathol. 2024; 28(3):387-392.

PMID: 39670140 PMC: 11633928. DOI: 10.4103/jomfp.jomfp_122_24.

Diagnostic potential of salivary IL-1β, IL-8, SAT, S100P, and OAZ1 in oral squamous cell carcinoma, oral submucous fibrosis, and oral lichen planus based on findings from a Sri Lankan cohort.

Senevirathna K, Mahakapuge T, Jayawardana N, Rajapakse J, Gamage C, Seneviratne B Sci Rep. 2024; 14(1):27226.

PMID: 39516476 PMC: 11549458. DOI: 10.1038/s41598-024-75735-0.

Effect of the gut microbiome and inflammation-related proteins on oral leukoplakia: a Mendelian randomization study and mediation analysis.

Da J, Ren Y, Liu S, Wang N, Wang L, Fu Z Front Oncol. 2024; 14:1443123.

PMID: 39386195 PMC: 11461448. DOI: 10.3389/fonc.2024.1443123.

Salivary biomarkers: a promising approach for predicting immunotherapy response in head and neck cancers.

Nejat Dehkordi A, Maddahi M, Vafa P, Ebrahimi N, Aref A Clin Transl Oncol. 2024; .

PMID: 39377974 DOI: 10.1007/s12094-024-03742-8.

References

Pries R, Wollenberg B . Cytokines in head and neck cancer. Cytokine Growth Factor Rev. 2006; 17(3):141-6. DOI: 10.1016/j.cytogfr.2006.02.001. View

Holmstrup P, Vedtofte P, Reibel J, Stoltze K . Long-term treatment outcome of oral premalignant lesions. Oral Oncol. 2005; 42(5):461-74. DOI: 10.1016/j.oraloncology.2005.08.011. View

van der Waal I . Potentially malignant disorders of the oral and oropharyngeal mucosa; terminology, classification and present concepts of management. Oral Oncol. 2008; 45(4-5):317-23. DOI: 10.1016/j.oraloncology.2008.05.016. View

St John M, Li Y, Zhou X, Denny P, Ho C, Montemagno C . Interleukin 6 and interleukin 8 as potential biomarkers for oral cavity and oropharyngeal squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 2004; 130(8):929-35. DOI: 10.1001/archotol.130.8.929. View

Sahebjamee M, Eslami M, AtarbashiMoghadam F, Sarafnejad A . Salivary concentration of TNFalpha, IL1 alpha, IL6, and IL8 in oral squamous cell carcinoma. Med Oral Patol Oral Cir Bucal. 2008; 13(5):E292-5. View

Rhodus N, Cheng B, Myers S, Miller L, Ho V, Ondrey F . The feasibility of monitoring NF-kappaB associated cytokines: TNF-alpha, IL-1alpha, IL-6, and IL-8 in whole saliva for the malignant transformation of oral lichen planus. Mol Carcinog. 2005; 44(2):77-82. DOI: 10.1002/mc.20113. View

Wong H, Pfeiffer R, Fears T, Vermeulen R, Ji S, Rabkin C . Reproducibility and correlations of multiplex cytokine levels in asymptomatic persons. Cancer Epidemiol Biomarkers Prev. 2008; 17(12):3450-6. DOI: 10.1158/1055-9965.EPI-08-0311. View

Mocellin S, Rossi C, Pilati P, Nitti D . Tumor necrosis factor, cancer and anticancer therapy. Cytokine Growth Factor Rev. 2005; 16(1):35-53. DOI: 10.1016/j.cytogfr.2004.11.001. View

Hodge D, Peng B, Cherry J, Hurt E, Fox S, Kelley J . Interleukin 6 supports the maintenance of p53 tumor suppressor gene promoter methylation. Cancer Res. 2005; 65(11):4673-82. DOI: 10.1158/0008-5472.CAN-04-3589. View

10.

Brill A . The TNM system for clinical staging of oral malignant tumors. Otolaryngol Clin North Am. 1979; 12(1):69-71. View

11.

van der Waal I, Schepman K, van der Meij E, Smeele L . Oral leukoplakia: a clinicopathological review. Oral Oncol. 1998; 33(5):291-301. DOI: 10.1016/s1368-8375(97)00002-x. View

12.

Axell T, PINDBORG J, Smith C, van der Waal I . Oral white lesions with special reference to precancerous and tobacco- related lesions: conclusions of an international symposium held in Uppsala, Sweden, May 18-21 1994. International Collaborative Group on Oral White Lesions. J Oral Pathol Med. 1996; 25(2):49-54. DOI: 10.1111/j.1600-0714.1996.tb00191.x. View

13.

Schepman K, van der Meij E, Smeele L, van der Waal I . Malignant transformation of oral leukoplakia: a follow-up study of a hospital-based population of 166 patients with oral leukoplakia from The Netherlands. Oral Oncol. 1998; 34(4):270-5. View

14.

Katakura A, Kamiyama I, Takano N, Shibahara T, Muramatsu T, Ishihara K . Comparison of salivary cytokine levels in oral cancer patients and healthy subjects. Bull Tokyo Dent Coll. 2008; 48(4):199-203. DOI: 10.2209/tdcpublication.48.199. View

15.

Frodge B, Ebersole J, Kryscio R, Thomas M, Miller C . Bone remodeling biomarkers of periodontal disease in saliva. J Periodontol. 2008; 79(10):1913-9. DOI: 10.1902/jop.2008.080070. View

16.

Hoffmann T, Sonkoly E, Homey B, Scheckenbach K, Gwosdz C, Bas M . Aberrant cytokine expression in serum of patients with adenoid cystic carcinoma and squamous cell carcinoma of the head and neck. Head Neck. 2006; 29(5):472-8. DOI: 10.1002/hed.20533. View

17.

Arellano-Garcia M, Hu S, Wang J, Henson B, Zhou H, Chia D . Multiplexed immunobead-based assay for detection of oral cancer protein biomarkers in saliva. Oral Dis. 2009; 14(8):705-12. PMC: 2675698. DOI: 10.1111/j.1601-0825.2008.01488.x. View

18.

Yan B, Wang H, Rabbani Z, Zhao Y, Li W, Yuan Y . Tumor necrosis factor-alpha is a potent endogenous mutagen that promotes cellular transformation. Cancer Res. 2006; 66(24):11565-70. DOI: 10.1158/0008-5472.CAN-06-2540. View

19.

Apte R, Krelin Y, Song X, Dotan S, Recih E, Elkabets M . Effects of micro-environment- and malignant cell-derived interleukin-1 in carcinogenesis, tumour invasiveness and tumour-host interactions. Eur J Cancer. 2006; 42(6):751-9. DOI: 10.1016/j.ejca.2006.01.010. View

20.

Brailo V, Vucicevic-Boras V, Cekic-Arambasin A, Alajbeg I, Milenovic A, Lukac J . The significance of salivary interleukin 6 and tumor necrosis factor alpha in patients with oral leukoplakia. Oral Oncol. 2005; 42(4):370-3. DOI: 10.1016/j.oraloncology.2005.09.001. View